Table 1 RAS mutations in CTCL patients:... | American Society of Hematology

Table 1

RAS mutations in CTCL patients: characteristics of patients with mutations

Characteristic	Patient 1	Patient 2	Patient 3	Patient 4
Diagnosis	CTCL, pleomorphic	Sézary syndrome	Mycosis fungoides	CTCL, CD30⁺
Mutation	KRAS (G13D)	NRAS (Q61K)	KRAS (G13D)	NRAS (Q61K)
Sex	Male	Female	Male	Male
Age, y	70	75	45	61
TNMB stages	T3 N3 M0 B0	T4 N3 M0 B1	T3 N3 M1 B0	T3 N3 M0 B0
Staging	IVA₂	IVA₂	IVB	IVA₂
Tissue	CATS	PBMCs	CATS	CATS
Skin	Disseminated papules and small tumors	Melano erythroderma without palmoplantar hyperkeratosis	Disseminated tumors with a size up to 5 cm diameter	Right shoulder singular 4 × 3-cm firm tumor
Lymphocytes, × 10³ μL	1.1	1.48	3.6	2.1
Sézary cells,%	None	20%-30%	None	None
CD4/CD8 ratio	4.3	6	16.7	1.3

Characteristic	Patient 1	Patient 2	Patient 3	Patient 4
Diagnosis	CTCL, pleomorphic	Sézary syndrome	Mycosis fungoides	CTCL, CD30⁺
Mutation	KRAS (G13D)	NRAS (Q61K)	KRAS (G13D)	NRAS (Q61K)
Sex	Male	Female	Male	Male
Age, y	70	75	45	61
TNMB stages	T3 N3 M0 B0	T4 N3 M0 B1	T3 N3 M1 B0	T3 N3 M0 B0
Staging	IVA₂	IVA₂	IVB	IVA₂
Tissue	CATS	PBMCs	CATS	CATS
Skin	Disseminated papules and small tumors	Melano erythroderma without palmoplantar hyperkeratosis	Disseminated tumors with a size up to 5 cm diameter	Right shoulder singular 4 × 3-cm firm tumor
Lymphocytes, × 10³ μL	1.1	1.48	3.6	2.1
Sézary cells,%	None	20%-30%	None	None
CD4/CD8 ratio	4.3	6	16.7	1.3

CATS indicates cryo-asserved tissue samples; and PBMCs, peripheral blood mononuclear cells.